FDA grants Vivet Therapeutics fast track designation for VTX-801 for Wilson disease

FDA grants Vivet Therapeutics fast track designation for VTX-801 for Wilson disease

Vivet Therapeutics announced it received FDA fast track designation for VTX-801, which is intended for treatment of Wilson disease.According to a press release, the investigational gene therapy will be assessed in a phase 1/ 2 clinical trial in order to determine the safety, tolerability and pharmacological activity of a single IV infusion in adult patients with Wilson disease. Vivet and Pfizer are collaborating on the clinical supply of VTX-80l for the trial.“With the FDA’s authorization of the [investigational new drug] application for VTX-801 — combined with Pfizer’sRead More

Share on facebook
Share on twitter
Share on linkedin